O'Neill E - Search Results

1

Enhancing [¹⁷⁷Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics.

Cheng J, Zink J, O'Neill E, Cornelissen B, Nonnekens J, Livieratos L, Terry SYA. Cheng J, et al. EJNMMI Res. 2024 Aug 13;14(1):73. doi: 10.1186/s13550-024-01135-0. EJNMMI Res. 2024. PMID: 39136880 Free PMC article.

2

Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy.

O'Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, Smart S, Lee BQ, Falzone N, Vallis KA, Konijnenberg MW, de Jong M, Nonnekens J, Cornelissen B. O'Neill E, et al. J Nucl Med. 2020 May;61(5):743-750. doi: 10.2967/jnumed.119.232934. Epub 2019 Nov 22. J Nucl Med. 2020. PMID: 31757844 Free PMC article.

3

Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy.

O'Neill E, Cornelissen B. O'Neill E, et al. Nucl Med Biol. 2022 May-Jun;108-109:44-53. doi: 10.1016/j.nucmedbio.2022.02.004. Epub 2022 Mar 4. Nucl Med Biol. 2022. PMID: 35276447 Review.

4

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent.

Fraser CR, Ajenjo J, Veal M, Dias GM, Chan C, O'Neill E, Destro G, Lau D, Pacelli A, Gouverneur V, Hueting R, Cornelissen B. Fraser CR, et al. EJNMMI Res. 2022 Aug 13;12(1):50. doi: 10.1186/s13550-022-00920-z. EJNMMI Res. 2022. PMID: 35962885 Free PMC article.

5

Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome.

O'Neill E, Mosley M, Cornelissen B. O'Neill E, et al. Theranostics. 2023 Feb 21;13(4):1302-1310. doi: 10.7150/thno.82101. eCollection 2023. Theranostics. 2023. PMID: 36923536 Free PMC article.

6

Combination Strategies to Improve Targeted Radionuclide Therapy.

Chan TG, O'Neill E, Habjan C, Cornelissen B. Chan TG, et al. J Nucl Med. 2020 Nov;61(11):1544-1552. doi: 10.2967/jnumed.120.248062. Epub 2020 Oct 9. J Nucl Med. 2020. PMID: 33037092 Free PMC article.

7

[¹²³I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.

Chan CY, Chen Z, Guibbal F, Dias G, Destro G, O'Neill E, Veal M, Lau D, Mosley M, Wilson TC, Gouverneur V, Cornelissen B. Chan CY, et al. J Nucl Med. 2023 Dec 1;64(12):1965-1971. doi: 10.2967/jnumed.123.265429. J Nucl Med. 2023. PMID: 37770109 Free PMC article.

8

⁸⁹Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma.

Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. Poty S, et al. Theranostics. 2020 Apr 27;10(13):5802-5814. doi: 10.7150/thno.44772. eCollection 2020. Theranostics. 2020. PMID: 32483420 Free PMC article.

9

Imaging PARP with [¹⁸F]rucaparib in pancreatic cancer models.

Chan CY, Chen Z, Destro G, Veal M, Lau D, O'Neill E, Dias G, Mosley M, Kersemans V, Guibbal F, Gouverneur V, Cornelissen B. Chan CY, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678. doi: 10.1007/s00259-022-05835-4. Epub 2022 May 26. Eur J Nucl Med Mol Imaging. 2022. PMID: 35614267 Free PMC article.

10

Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control.

Russell SN, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, Hazini A, Willenbrock F, Gordon-Weeks AN, Mukherjee S, Tesson M, Morton JP, O'Neill E, Jones KI. Russell SN, et al. Among authors: o neill e. Gut. 2025 Jan 9:gutjnl-2024-333492. doi: 10.1136/gutjnl-2024-333492. Online ahead of print. Gut. 2025. PMID: 39788719

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters